Monthly Archives: January 2021

Turning to psychedelics to treat mental health - Video - NEWS 1130 Rogers Media uses cookies for personalization, to customize its online advertisements, and for other purposes. Learn more or change your cookie preferences. Rogers Media supports the Digital Advertising Alliance principles. By continuing to use our service, you agree to our use of cookies.We use cookies (why?) You can change cookie preferences. Continued site use signifies consent.

There may be a psychedelic solution to the mental health problem in Canada. Pat Taney looks at the state of mental health in this country, and why scientists say psychedelics can be a game changer and help heal minds.

Jan 22, 2021, 3:32 PM

We've sent an email with instructions to create a new password. Your existing password has not been changed.

{* backButton *}{* forgotPassword_sendButton *}

Subscribe to NEWS 1130 newsletters

I understand that I can withdraw my consent at any time

Loading newsletters

{* mergeAccounts *}

{* public_profileBlurb *}

{* public_displayName *}

Updating your profile data...

You have activated your account, please feel free to browse our exclusive contests, videos and content.

You have activated your account, please feel free to browse our exclusive contests, videos and content.

An error has occurred while trying to update your details. Please contact us.

Or

{* traditionalSignIn_signInButton *}

Or

{* backButton *}{* traditionalSignIn_signInButton *}

Please confirm the information below before signing up.

Subscribe to NEWS 1130 newsletters

I understand that I can withdraw my consent at any time

By checking this box, I agree to the terms of service and privacy policy of Rogers Media.

{* backButton *}{* createAccountButton *}

We didn't recognize that password reset code. Enter your email address to get a new one.

Sorry we could not verify that email address. Enter your email below and we'll send you another email.

Or

{* loginWidget *}

View post:

WATCHING NOW Turning to psychedelics to treat mental health - News 1130

New research suggests that the publics perception of the potential harms of magic mushrooms is not in line with drug laws. The study, which appears in the Journal of Psychopharmacology, found that psilocybin-containing mushrooms are considered less dangerous than alcohol, tobacco, and other substances.

I am a psychopharmacologist at the University of Liverpool, so I have a great interest in how substances affect the brain and behavior, said study author Carl Roberts, a lecturer in the universitys department of psychology.

I have long been following the resurgence in research with psychedelics such as psilocybin for therapeutic potential. I knew this research area had been gaining quite a lot of attention recently. I also knew that the data on actual harm of magic mushroom use suggested that toxicity and abuse potential was low.

However, they are classified as a Class A drug in the UK suggesting the same relative harm as heroin and cocaine, Roberts explained. So I was interested to see what the publics perceptions of harms around magic mushrooms were i.e. are they in line with government legal classifications, or are they in line with the scientific evidence?

For their study, the researchers asked 151 participants to rank the dangerousness of ten different substances: alcohol, tobacco, prescription opiates, heroin, cocaine, ecstasy, magic mushrooms, cannabis, LSD, and GHB.

The participants were recruited from various websites and social media pages that provide information about recreational drug use. Nearly half of them were from the United Kingdom, while approximately 21% were from the United States. The remaining participants were from countries in the European Union.

Despite magic mushrooms being a Schedule I substance in the United States and a Class A substance in the United Kingdom the most restrictive categories the researchers found that most participants considered magic mushrooms to be relatively safe compared to the other substances.

Those who had previously used magic mushrooms ranked it as the least dangerous substance. Those who had never used magic mushrooms, on the other hand, ranked it as the second to least most dangerous substance. (Non-users ranked cannabis as the least dangerous substance.)

Both people with a history of using magic mushrooms, and those who were non-users considered magic mushrooms to be less dangerous than heroin (Class A), cocaine (Class A), prescription pain-killers (legal with prescription), GHB (Class C), ecstasy (Class A), tobacco (legal) and alcohol (legal), Roberts told PsyPost.

This suggests a general perception of harm of magic mushrooms that is in line with data on actual harm (abuse potential and toxicity) and the scientifically recognized relative harms of psilocybin mushrooms compared to other drugs. This indicates that public health messaging based on scientific evidence about relative harms of drugs are seen as more credible information sources than government legal drugs classification systems.

But the study like all research includes some caveats.

This was an online survey style study. As such, there is a potential selection bias here, in that perhaps only participants who are interested in this research area took part. Thus a much larger random sample would be necessary to properly gauge general public perception, Roberts explained.

In addition, this study provides no information about potential negative long-term health effects of using psilocybin mushrooms in controlled and uncontrolled settings, which is something that requires further research.

While magic mushrooms were ranked as less dangerous than several other legal and illegal substances in our sample, this does not mean that they are considered to have no harm at all, Roberts added. Rather, that relative to other drugs, perception of harm is low. Indeed, there are documented cases of adverse reactions and other complications associated with magic mushroom use.

The study, Perceived harm, motivations for use and subjective experiences of recreational psychedelic magic mushroom use, Carl A Roberts, Isaac Osborne-Miller, Jon Cole, Suzanne H Gage, and Paul Christiansen.

Read this article:

The publics perception of the harms of magic mushrooms is in line with science but not with ... - PsyPost

La Jolla, California--(Newsfile Corp. - January 19, 2021) - Tryp Therapeutics (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the upcoming Investing in Psychedelics Conference hosted by The CSE (Canadian Securities Exchange).

Investing in Psychedelics Conference:Date: Wednesday, January 20th, 2021Registration: https://promo.cfnmedia.com/psychedelics

We look forward to speaking on the Drug Developers Panel at this weeks Psychedelic Conference, said Jim Kuo, CEO at TRYP Therapeutics. As we move our development pipeline forward into the clinic, continuing to share our story with investors, expanding our shareholder base is critical to the growth of our company and were excited to participate in this event with a number of our peers.

Investors or Shareholders interested in participating in this event can do so by registering at https://promo.cfnmedia.com/psychedelics .

Each live panel will last about 40 minutes with 15 minutes of Q&A. Panel #1 will begin just before 1:00pm EST, Panel #2 just before 2:00pm EST and Panel #3 just before 3:00pm EST.

Panel Segmentation:

Panel 1. Drug Developers - Unlocking the Value Through IP (Tom Zuber, moderator)

Panel 2. IP - Pitfalls and Potentials (Paul Rosen, moderator. David Wood is a panelist)

Panel 3. Bankers and Capital Markets (Josh Lawler, moderator)

About Tryp Therapeutics:

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp's psilocybin-for-neuropsychiatric disorders, or PFN, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.

Tryp's lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States.

Story continues

In addition to its PFN Program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Soft tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for Orphan Drug status.

Contact:

For inquiries, please contact us at:

TRYP Investor RelationsT: 1-833-811-TRYP (8797)E: investors@tryptherapeutics.com

Forward-Looking Information

Certain information in this news release, including statements relating to the anticipated date that the Common Shares will commence trading on the Canadian Securities Exchange constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Prospectus available at http://www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Not for Dissemination in the United States or Distribution to U.S. Newswire Services

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72329

Follow this link:

Tryp Therapeutics Invited to Present at "Investing in Psychedelics" Conference - Yahoo Finance

While the public focus remains on COVID vaccines, the Therapeutic Goods Administration (TGA) continues to evaluate a range of proposals around the provision of medical treatments in Australia.

The regulatory body is currently considering whether psychiatrists should be allowed to prescribe MDMA and psilocybin to treat mental illness. The TGA will announce its interim decision on February 3, and will make a final ruling on April 22.

Psychedelic drugs for the treatment of mental illness represent a promising area. And any new treatment which could help people suffering particularly in the wake of the pandemic may seem like a good thing.

But until Australia engages in further research into the therapeutic potential of these drugs, we believe its too soon to make them available as medicines.

Increasing research evidence suggests MDMA, commonly known as ecstasy, could be an effective adjunct to psychotherapy for people with post-traumatic stress disorder (PTSD).

Meanwhile, clinical trials of psilocybin, the psychoactive component of magic mushrooms, show it could assist psychotherapy in the treatment of anxiety and depression, addiction, and a range of other mood disorders.

On this basis, in July 2020, an organisation called Mind Medicine Australia made an application to the TGA requesting MDMA and psilocybin be classified as Schedule 8 controlled medicines.

MDMA and psilocybin are currently classified as Schedule 9 prohibited drugs. Other examples of Schedule 9 drugs include heroin and methamphetamine.

As Schedule 8 controlled medicines, MDMA and psilocybin would sit alongside drugs like dexamphetamine, morphine and some forms of medical cannabis. Some of these and other Schedule 8 drugs such as ketamine and cocaine are used recreationally.

If the TGA reclassifies MDMA and psilocybin, Australia would be the first country in the world to recognise these drugs as legitimate medicines.

Read more: Psychedelics to treat mental illness? Australian researchers are giving it a go

Early research suggesting psychedelics had therapeutic potential lapsed after 1971, when the drugs were made illegal around the world. But it resumed early in the 2000s, manifesting into an international renaissance in psychedelic science.

Australia was a little later to get involved than some countries, but in the past 18 months weve succeeded in initiating clinical research locally.

Edith Cowan University, Monash University, the University of Melbourne, and St Vincents hospitals in Melbourne and Sydney all have research on psychedelic-assisted therapies either in the pipeline or already underway. The trial at St Vincents hospital in Melbourne is the first to have started recruiting participants.

These trials aim both to contribute to the research happening globally, and to demonstrate that Australia has the regulatory processes, people and infrastructure to provide these treatments safely and effectively.

Read more: Weekly Dose: ecstasy, the party drug that could be used to treat PTSD

There are three key reasons why Australia is not yet ready for MDMA and psilocybin to be rescheduled as medicines by the TGA.

1. No accredited training

Australia has very few health-care professionals trained to provide psychedelic-assisted psychotherapy. These drugs produce powerful changes in consciousness that could lead to psychological harm, rather than healing, when given to unsuitable patients, or by health-care workers without the necessary training.

2. Prohibitive costs

Medical cannabis is only legally available in pharmaceutical formulations the actual plant is not available as a medicine. This makes medical cannabis expensive. Only 3.9% of Australians using cannabis for medical reasons access it legally. We expect pharmaceutical-grade MDMA and psilocybin will also be expensive to access.

3. Going underground

Like medical cannabis, were concerned that lack of access and prohibitive costs will mean more people will access existing unregulated MDMA and psilocybin treatment services. This puts people at risk, since theres no quality control of either the drugs or the therapists.

Should these issues arise, our efforts over recent years to finally establish psychedelic medicine in Australia could be undone.

Given these concerns, we believe its highly unlikely the TGA will decide to reschedule MDMA and psilocybin as medicines at this stage.

And while emerging evidence is continuing to suggest these drugs can be effective adjuncts to psychotherapy, we believe the application was made without sufficient regard to the universally accepted process of new drug approval.

We need to see Phase 3 clinical trials completed before any informed decisions can be made (the trials in Australia have not yet reached Phase 3). This approval process is important so we know the drugs are effective and safe, including understanding any side effects.

By way of comparison, we know Pfizer wouldnt apply for TGA approval for a new antidepressant before completing Phase 3 research. Even the COVID-19 vaccines Pfizer, AstraZeneca and Moderna are fast-tracking internationally have been required to complete stringent, widely scrutinised Phase 3 trials.

Read more: How will COVID-19 vaccines be approved for use in Australia?

Current and future Australian research in this space will offer a crucial pathway for therapists to learn how to provide psychedelic-assisted psychotherapy. This is an important step before Australia is ready for MDMA and psilocybin to be approved as medicines.

Moving forward, we anticipate Australian health-care professional registration boards will come to acknowledge psychedelic-assisted psychotherapy as a speciality area of training, and will need to develop accredited training programs to meet the demand for appropriately qualified therapists.

Notably, none of the current research into psychedelic-assisted treatments for mental illness in Australia is receiving government funding. Government support will be important to extend this research beyond the early-phase trials, and ultimately will be crucial for the widespread rollout of this treatment.

Finally, to ensure equitable access, psychedelic-assisted therapies will need to be embedded within the public health-care system and supported by the Pharmaceutical Benefits Scheme.

Our submission to the TGA, along with others, will be made public on February 3, when the TGA announces its interim decision on the rescheduling of psilocybin and MDMA.

See the original post:

Will Australia legalise ecstasy and magic mushrooms to treat mental illness? Here's why it's still too soon - The Conversation AU

Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly.

"Personally, I have over 20 years of experience investing and working in the private and public markets," shared Weisblum to start the interview. "I have served on the board of NASDAQ listed biotech companies, and have consulted and worked with licensing technologies from various universities."

"Why did you choose this particular space?" asked Jolly. "There's a lot of research that has been done, there's a lot of positive studies and clinical trials that are on-going," said Weisblum. "It is estimated that by 2027 this will be a $6.85 billion market according to Data Bridge Market Research," he shared. "We see this as a tremendous opportunity, not just for the investors and the upside, but to actually develop and bring therapeutics to the market that could actually help people."

Weisblum then elaborated on the therapeutic applications of psychedelics. "A lot of the studies have shown very positive data that anxiety, depression, and PTSD respond very well to some of the psychedelic drugs," explained Weisblum. "We see a tremendous opportunity for people that have not responded to traditional therapies," he continued, adding that the Company is currently focused on combining traditional therapeutics with psychedelic research for their potential role in treating individuals with CNS disorders.

Jolly then asked about the Company's investment potential and primary objectives. "Neurological and central nervous system disorders are what our focus is on," said Weisblum. He then explained that the Company is hopeful that the ongoing studies involving the use of psychedelics to treat anxiety and depression will help them determine if these compounds can be used with their proprietary IP to help patients with Parkinson's and other disorders and conditions.

Story continues

The conversation then turned to the Company's accomplishments in 2020. "What I'm really proud of is our Scientific Advisory Board," shared Weisblum. "I think we have some of the most well-regarded, reputable people in the industry."

"What are you hoping to accomplish in the next two to three quarters?" asked Jolly. "We're moving forward with our LSD and psilocybin study for the effects on Parkinson's," said Weisblum. "In addition, we are doing a study with our peptide for multiple sclerosis and we're looking forward to receiving those data points and moving those forward in 2021," he continued. "We are also working on a couple of technologies within various universities that we hope will consummate in 2021."

"How did you get involved with the University of Maryland?" asked Jolly. "Through prior experience with a biotech and NASDAQ listed company," responded Weisblum. "I helped transform that company into a full biotechnology company, and I have developed relationships with various universities and tech transfer departments," he explained. "A lot of it is relationship-based, and I think that's one of the strengths that we have as a team over here."

To close the interview, Weislbum shared that the Company will continue to strive to advance the combination of therapeutics and psychedelics in an effort to make a difference in patients with a variety of disorders.

To hear Eric Weisblum's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7777291-silo-pharma-inc-discusses-the-potential-of-merging-traditional-therapeutics-with-psychedelic-res

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. Silo's mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit http://www.silopharma.com.

Investor Relations Contact:

Hayden IRBrett Maas646-536-7331Email: brett@haydenir.com

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:Stock Day Media(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72408

Here is the original post:

Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast - Yahoo Finance

January21, 20215 min read

Its a question I last considered in the nineties. I first wondered if Leary was CIA when Black Panther Eldridge Cleaver put his ass under revolutionary house arrest in Algeria after he escaped from prison with the help of the Weather Underground. Why would the Weather Underground choose Leary out of all the black political prisoners in the country? Many of them are still in jail fifty years later.Dont need a weatherman to tell which way the wind blows.

RELATED:A Crash Course On Opportunites In Psychedelic Medicine

In the nineties, The Beastie BoysGrand Royal(the magazine, not the label), with its colorfully painted cover of Lee Scratch Perry, askedWas The Sixties Revolution A Government Plot?According to the article, Leary tuned in, turned on and turned coat. Mark Riebling, the author, extensively details the CIAs history with LSD and Learys relationship with the intelligence community. It turns out, Riebling is co-founder and former research director of the Center for Tactical Counterterrorism. Cat knows his espionage (although, if I listen to my Discordian home-slice, Robin, Rieblings article couldve just as easily been a disinformation plant). Who the fuck knows? This shit reminds me of the hype promoting the computer revolution in the 90s. And Leary was there, too, before his head was sawed off and turned into a block of ice.

But the question inMy Psychedelic Love Storyis whether or not Joanna Harcourt-Smith is CIA. In an early scene, Allen Ginsberg, with revolutionary indignation, and incantatory imprecations, accuses Ms. Smith of being a sex-tool of the CIA. I laughed and laughed. Out of the bearded mouth of NAMBLA.

Joannas tale is a real eat me/drink me drop down the rabbit hole. Heres a taste.

Shes hanging out with the Stones after hooking up with some cat the Stones nicknamed Tommy the Tumbling Dice and stuck him on a 45. Presidential hopeful George McGovern asks the Stones to do a gig at one of his campaign rallies but sympathy from the devil aint in the stars so she ends up on the floor of Diane Von Furstenbergs Manhattan apartment, lounging on a mink blanket. Diane hands her the phone and its international arms dealer Michel Hauchard. Over drinks at the Regis, he tells her he got a check for two hundred fifty thousand dollars for Learys attempt to emulate Aleister Crowley withConfessions of a Hope Fiend(apparently, Leary believed he was the reincarnation of the Great Beast, probably in the same way Crowley believed he was the reincarnation of Eliphas Levi). Why? Leary signed over thirty percent of any book royalties he earned to Hauchard. In return, Hauchard had his ass thrown in jail.

RELATED:5 Ways Technology Is Powering The Psychedelic Movement

Eventually, Joanna and Tumbling Tommy end up at Learys chalet in Laucern, Switzerland. Instantly, shes impressed by the Porsche-driving High Priest who tells her after dosing some Clear Light acid Youve come to free me!

Curiously, this film has a moment tangentially related to Stan Grofs theories of psychedelics and the trauma of the birth canal, discussed inmy reviewof The Way of the Psychonaut. Before coitus, Leary shows a nude and bejeweled Joanna x-rays of the brain pictured in an issue of Life magazine. Pointing at the x-ray, he tells herI am going to make love to you here.It reminded me of a Charles Manson seduction in Ed SandersThe Family.

The story she tells is pretty incredible, justifying Morris use of Disney animation clips and imagery from Crowleys Thoth tarot deck. In fact, the films design is one aspect I love most. His kaleidoscopic use of archival footage gives it the look of the sixties underground tabloid,The San Francisco Oracle.The other aspect I love is Joanna Harcourt-Smith.

I cant believe I am about to write this sentence, but she is a woman who operates from her heart chakra. She is quite moving in openly telling her story. Was she an operative planted by the CIA?

Its complicated. Her best response:

A lot of people have been manipulated to manipulate history.

Sadly, on October 11, 2020, she succumbed to breast cancer at her home in Santa Fe, New Mexico, surrounded by her family. She was seventy-four years old.Errol Morris saidof Ms. Harcourt-Smith, I was privileged to show her the completed movie just before she died. She watched it, Ive been told by her family, six or seven times the week of her death and she loved it.

View post:

A Look into the Life of Tim Leary Through the Eyes of His Psychedelic Lover - Green Entrepreneur